ovid
therapeutics
present
child
neurology
society
international
child
neurology
association
cns
icna
virtual
congress
four
abstracts
gaboxadol
clinical
development
program
angelman
syndrome
fragile
x
syndrome
presented
new
york
globe
newswire
ovid
therapeutics
nasdaq
ovid
biopharmaceutical
company
committed
developing
medicines
transform
lives
people
rare
neurological
diseases
today
announced
four
abstracts
gaboxadol
clinical
development
program
presented
child
neurology
society
international
child
neurology
association
cns
icna
virtual
congress
taking
place
october
october
presentations
include
additional
data
analyses
phase
rocket
clinical
trial
individuals
fragile
x
syndrome
data
seizure
eeg
outcomes
phase
stars
clinical
trial
individuals
angelman
syndrome
encore
presentations
study
caregiver
insights
angelman
syndrome
utility
clinical
global
impression
cgi
scale
studying
outcomes
neurodevelopmental
conditions
ovid
passionately
committed
development
address
significant
unmet
medical
need
individuals
angelman
fragile
x
syndromes
two
neurological
conditions
tremendous
caregiver
family
impact
approved
treatment
options
either
said
amit
rakhit
md
mba
president
chief
medical
officer
ovid
data
contribute
evolving
scientific
exchange
advancing
discussion
around
neurodevelopmental
conditions
caregiver
concerns
urgency
develop
new
medicines
details
presentations
follows
title
caregiver
insight
core
domains
angelman
syndrome
adera
et
al
poster
number
title
phase
rocket
trial
investigating
gaboxadol
adolescents
young
adults
fragile
x
syndrome
et
al
poster
number
title
adaptation
utility
clinical
global
impression
scale
studying
treatment
outcomes
neurodevelopmental
conditions
jaeger
et
al
poster
number
title
stars
phase
safety
tolerability
exploratory
efficacy
study
gaboxadol
adolescents
adults
angelman
syndrome
seizure
eeg
outcomes
wang
et
al
poster
number
ovid
therapeutics
ovid
therapeutics
new
biopharmaceutical
company
using
approach
develop
medicines
transform
lives
patients
rare
neurological
disorders
ovid
broad
pipeline
potential
medicines
company
advanced
investigational
medicine
gaboxadol
currently
clinical
development
treatment
angelman
syndrome
fragile
x
syndrome
ovid
also
developing
soticlestat
collaboration
takeda
pharmaceutical
company
limited
potential
treatment
rare
developmental
epileptic
encephalopathies
dee
information
ovid
please
visit
gaboxadol
believed
delta
Î´
gaba
receptor
agonist
development
first
investigational
drug
specifically
target
disruption
tonic
inhibition
central
physiological
process
brain
thought
underlying
cause
certain
neurodevelopmental
disorders
demonstrated
laboratory
studies
animal
models
selectively
activate
gaba
receptors
found
extrasynaptic
space
outside
synapse
thereby
impact
neuronal
activity
modulation
tonic
inhibition
ovid
developing
treatment
angelman
syndrome
fragile
x
syndrome
potentially
restore
tonic
inhibition
thereby
address
several
core
symptoms
conditions
syndromes
underlying
pathophysiology
includes
disruption
tonic
inhibition
modulated
gaba
receptors
preclinical
studies
observed
improved
symptoms
angelman
syndrome
fragile
x
syndrome
compound
also
previously
tested
patients
exposure
observed
favorable
safety
bioavailability
profiles
ovid
conducting
pivotal
phase
clinical
trial
angelman
syndrome
neptune
completed
phase
clinical
trial
fragile
x
syndrome
rocket
received
rare
pediatric
disease
designation
fda
treatment
angelman
syndrome
fda
also
granted
orphan
drug
fast
track
designations
treatment
angelman
syndrome
fragile
x
syndrome
addition
european
commission
ec
granted
orphan
drug
designation
treatment
angelman
syndrome
patent
trademark
office
granted
ovid
patents
directed
methods
treating
angelman
syndrome
fragile
x
syndrome
using
issued
patents
expire
without
regulatory
extensions
statements
press
release
includes
certain
disclosures
contain
statements
including
without
limitation
statements
regarding
potential
benefits
clinical
regulatory
development
likelihood
data
support
future
development
association
data
treatment
outcomes
identify
statements
contain
words
appears
believes
statements
based
ovid
current
expectations
assumptions
statements
relate
future
subject
inherent
uncertainties
risks
changes
circumstances
may
differ
materially
contemplated
statements
neither
statements
historical
fact
guarantees
assurances
future
performance
important
factors
could
cause
actual
results
differ
materially
statements
include
uncertainties
development
regulatory
approval
processes
fact
initial
data
clinical
trials
may
indicative
guarantees
final
results
clinical
trials
subject
risk
one
clinical
outcomes
may
materially
change
patient
enrollment
continues
patient
data
become
available
additional
risks
could
cause
actual
results
differ
materially
statements
set
forth
ovid
filings
securities
exchange
commission
caption
risk
risks
may
amplified
pandemic
potential
impact
ovid
business
global
economy
ovid
assumes
obligation
update
statements
contained
herein
reflect
change
expectations
even
new
information
becomes
available
contacts
investors
media
ovid
therapeutics
investor
relations
public
relations
irpr
investors
argot
partners
maeve
conneighton
ovid
media
argot
partners
joshua
mansbach
ovid
media
dan
budwick
dan
